When new medicines come to market slowly and at high prices, people can’t always get the treatments they need.
We believe there’s a better way:
Imagine a world where new medicines come to market faster.
Imagine a world where new medicines are markers for customer value.
Imagine a world where people could focus on healing and not the price tag.
Alexis Borisy is a leading biotechnology entrepreneur and investor with more than 25 years of experience. He founded CombinatoRx in 1999 and is the co-founder of Foundation Medicine, Blueprint Medicines, Celsius Therapeutics and Relay Therapeutics. He's also a founding investor for Editas Medicine, Magenta Therapeutics, Revolution Medicines and Thrive Earlier Detection. Alexis is the Vice Chairman of the Board of Trustees of the Boston Museum of Science. He holds a master's degree in chemistry and chemical biology from Harvard University and a B.S. in chemistry from the University of Chicago.Chairman and CEO
Melanie Nallicheri is a healthcare and life sciences executive with nearly three decades of experience. Melanie served as Chief Business Officer and Head, Biopharma for Foundation Medicine; Senior Vice President, Corporate Strategy and Business Development, McKesson Distribution Solutions and McKesson Data & Analytics; and Senior Vice President, Corporate Development at Geron Corporation. She holds an MBA with honors from Columbia Business School, and an M.S. in business and economics from WHU Otto Beisheim School of Corporate Management.President and Chief Operating Officer
Robert Forrester has more than two decades of experience serving as chief executive officer or chief financial officer for both private and public biopharma companies. Prior to joining EQRx, Robert was CEO of Verastem Oncology, Chief Operating Officer or Chief Financial Officer at Forma Therapeutics, CombinatoRx (now ZLCS), and Coley Pharmaceutical Group. Robert also served as Managing Director of the Proprietary Investment Group at MeesPierson. He holds a LL.B. from Bristol University.CXO
Sue Hager brings more than two decades of life sciences leadership expertise to EQRx. She served as Senior Vice President of Corporate Communications, Government Affairs and Patient Advocacy for Foundation Medicine. Sue was Senior Vice President, Corporate Communications and Government Affairs for Myriant Corporation and held leadership positions at Targanta Therapeutics, Coley Pharmaceutical Group, and Bayer Healthcare. She holds an MBA and a B.S. degree in biology with honors from Northeastern University.Chief Communications Officer,
SVP Corporate Affairs and Citizenship
Co-founders & Advisors
- Peter Bach, MD Leading authority on health policy and reimbursement; director of the Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Sandra Horning, MD Expert clinical drug developer; former executive vice president, chief medical officer and global head product development, Genentech/Roche
Want to work with us?
We’re hiring and can’t wait to meet you.
We're in the news
Stay up to date on all things EQRx.
A 'radical proposition': A health care veteran tries to upend the system and bring drug prices downRead More
A Pharma Startup Launches With $200 Million In Funding And A Strategy To Make Drugs Faster, CheaperRead More
Alexis Borisy and Melanie Nallicheri on The Long Run podcast with Luke TimmermanRead More
Get In Touch.
Stay in the loop.
50 Hampshire StreetTwo-hour street parking is available. There are also several parking garages in the surrounding area.
Cambridge, MA 02139